Guggenheim Reiterates Buy Rating on Tango Therapeutics, Inc. (TNGX)

Market Context

Tango Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $25.58 with a market capitalization of $1.0B. The stock has gained 299.1% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tango Therapeutics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Tango Therapeutics, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 12, 2026	Guggenheim	Buy	N/A
Jul 17, 2026	Mizuho	Outperform	N/A
Jul 15, 2026	JP Morgan	Overweight	N/A
Jun 29, 2026	Canaccord Genuity	Buy	N/A
Jun 26, 2026	Jefferies	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View TNGX Stock Page